• 首页
  • 有机食品
  • 人气菜谱
  • 餐饮管理
  • 糖酒会
  • 果蔬分类
  • 卫生安全

Celartics Biopharma's dendritic cell-based vaccine against COVID-19 infection found to efficiently produce viral antigen-specific T lymphocytes

2020-05-22   

Results from ongoing study suggest the major role of Celartics' Cov-DCVax in preventing viral infection of COVID-19 and in controlling progression of the virus-associated diseasesBeijing, May 22, 2020, Celartics Biopharma announced today the filing of a patent application covering a novel dendritic cell (DC)-based vaccine, Cov-DCVax, to fight viral infection of COVID-19. The results, led by Celartics research team, demonstrate that using the proprietary engineered DC technology by targeting nucleoprotein (NP) of COVID-19, NP-specific cytotoxic CD8+ T cells from naive T lymphocytes can be efficiently induced and massively expanded in culture. The antigen-loaded DCs and viral antigen-specific T cells have great potentials in preventing viral infection and in controlling progression of virus-associated diseases, respectively.

Dendritic cells are the most potent professional antigen-presenting cells that can engulf and process viral or tumor antigens. Once DCs are loaded with viral antigen and become activated, they acquire the ability to educate naïve T lymphocytes, promoting these T cells to differentiate into antigen-specific cytotoxic T cells that can fight virus. Primary blood DCs constitute 1% of immune cells in peripheral blood and are not able to grow in culture. Manufacturing clinical grade DC with the conventional DC method, therefore, needs quite large amount of blood and is very costly, limiting DC’s application as a preventive vaccine against viral infection. To overcome various technical hurdles associated with the conventional DC method, Celartics Biopharma has developed an innovative engineered DC technology, which enables primary blood DCs from a few milliliters of peripheral blood to grow in culture, generating large amounts of highly activated DCs suitable for multiple clinical applications. These engineered DCs exhibit vastly improved antigen-loading capability and efficient lymphoid tissue homing ability due to high expression of the chemokine receptor, CCR7. In addition, the manufacturing cost for generating engineered DCs is significantly reduced. “The engineered DCs are safe to use, as demonstrated in animal studies and pilot clinical trial in cancer immunotherapy”, said Yang Yu, CEO of Celartics Biopharma

Current vaccine strategies for COVID-19 include mRNA vaccine, DNA vaccine, adenovirus vector-based vaccine and inactivated virus vaccine, with the goal of generating neutralizing antibody that reacts to Spike, the viral surface protein of COVID-19. The neutralizing antibody blocks entry of virus to host cells through ACE2 receptor. Accumulating evidences have suggested that developing permanent immunity remains challenging, exclusively by targeting heavily glycosylated Spike protein or rapidly mutating viral surface proteins such as influenza HA. Differing from these vaccine strategies, the engineered DCs are designed to empower T cells to fight virus. DC-educated T cells recognize viral antigenic peptides complexed with HLA molecules on the surface of virus-harboring host cells and launch subsequent attack to eliminate virus. Furthermore, a given viral protein in host cells is processed into multiple antigenic peptides that are bound to distinct HLA molecules, this provides many targets for antigen-specific T cells to attack. Unlike Spike protein, the NP protein of COVID-19 is less likely to mutate and also share 91% amino acid sequence homology with the counterpart of SARS virus. “The Cov-DCVax is designed to develop long-lasting protective immunity in human to fight both COVID-19 and SARS viruses”, said Yang Yu.

In last February, Celartics Biopharma announced the development of Human Dendritic Cell and Data Repository (HDCR), in order to meet urgent demands in fighting deadly virus outbreak and cancer. HDCR prepares human blood dendritic cells from healthy individuals in GMP facility, coupled with data analysis covering immunophenotyping and HLA typing. These engineered DCs are stored in liquid nitrogen and are readily available when needed, in supporting cell-based vaccination or immunotherapy. HDCR also serves as the platform technology provider to research institutions and pharmaceutical industries. The ultimate goal of HDCR is to bring in a feasibility of dendritic cells as a new form of preventive vaccines for rapidly evolving viruses. The Cov-DCVax vaccine is intended for generating long-lasting protective immunity in high risk individuals, while the viral antigen-specific T cells provide immediate therapeutic protection in controlling the progression of COVID-19-associated disease. "The current research progress and patent application enhance the spectrum of possible collaborators and partners. We are delighted that our scientific team has made solid progress in developing such unique Cov-DCVax vaccine, which may potentially yield benefits useful to high risk population, considering current global impact and severity of COVID-19 pandemic", said Yang Yu, CEO of Celartics Biopharma.


About Celartics Biopharma, Inc. Celartics Biopharma is a biotechnology company, located at Dongsheng International Science Park, Beijing. The company focuses on developing innovative cell-based immunotherapies for human cancer and viral diseases. The Company seeks rapidly advancing these technologies through pre-clinical and Phase I and II clinical trials, centering on DC therapeutic vaccine and adoptive T cell transfer therapies for treating solid cancer and leukemia. The company also seeks potential collaborators and partners for joint development through the proprietary technology platforms.

Ph.D., Chief Technology Officer, Celartics Biopharma, Inc.

Company :Celartics Biopharma Inc., Ltd.  

Contact: Huan Zhang,

Phone:010-6295 5880

Email: lily@celartics.com

Web:http://www.celartics.com/


免责声明:本文转载自其它媒体,转载目的在于传递更多信息,并不代表本网赞同其观点和对其真实性负责,亦不负任何法律责任。 本站所有资源全部收集于互联网,分享目的仅供大家学习与参考,如有版权或知识产权侵犯等,请给我们留言。

最新

  • 用心缔造 纯乳鲜香 辉山淳轩亮相2024HOTELEX上海展

    2024年3月27日-3月30日,第三十二届上海国际酒店及餐饮业博览会(以下简称HOTELEX)在国家会展中心(浦西·虹桥)盛大举办,越秀乳业旗下B2B专业品牌辉山淳轩Senscious于本次博览会惊艳亮相,越秀辉山党委书记、总经理韩春辉出席大会。
  • 辉山零蔗糖酸奶摘星iSEE全球美味奖,营养美味征服世界味蕾

    辉山零蔗糖酸奶摘星iSEE全球美味奖,营养美味征服世界味蕾
  • 第六届iSEE创新品牌百强榜公布!辉山牛奶旗下多炫和鲜博士成功上榜!

    3月8日,备受瞩目的第六届iSEE创新品牌百强榜正式揭晓,辉山牛奶旗下多炫和鲜博士两大知名品牌成功上榜,明星产品多炫冰淇淋酸奶系列和鲜博士4.3g娟姗鲜牛乳入围百强。
  • iSEE全球食品创新奖复审结果出炉 辉山牛奶两款产品入围百强

    3月8日,备受瞩目的第六届iSEE创新品牌百强榜正式揭晓,辉山牛奶旗下两款明星产品——多炫冰淇淋酸奶&鲜博士4.3g娟姗鲜牛乳成功上榜。
  • 鲜博士一斤鲜牛奶上市啦!1袋即可满足每日所需70%钙

    新学期的旅程扬帆起航,学生们重返熟悉的校园生活,随着学业任务与生活节奏的突然转变,难免使得孩子们脑力超负荷运转,造成身体与精神上的能量消耗,这时候,每天保持充足的营养摄入显得尤为重要。辉山牛奶适时推出全新新品——鲜博士一斤鲜牛奶,凭借更实惠、更营养、更保鲜的产品优势,以及1袋即可满足人体每日所需70%钙的吸睛卖点,备受消费者关注。
  • 辉山牛奶开学季又有新动作?酸奶“搭子”还能这么玩

    随着春风拂面,广大学子们满怀期待地回归校园,开启了新学期的学习生活。在这个充满活力和希望的季节,辉山牛奶特别策划了一系列开学季活动——“喝辉山吃鲜一,开学季考第一”,给广大师生和家长带来健康与活力的双重惊喜,为新学期讨个好彩头!
  • 2024功能食品健康峰会在吉隆坡圆满落幕

    在马来西亚吉隆坡召开的《2024功能食品健康峰会》(Functional Foods for Wellness Summit KL 2024)于3月7日落下了帷幕。此次峰会得到了国际益生菌协会(IPA)、马来西亚膳食补充剂协会(MADSA)、日本健康产经传媒、泰国健康食品和补充剂协会 (HFSA)、营养食品专家倡导委员会 (ENAC)的大力支持。来自中国、马来西亚、印度尼西亚、印度、泰国、日本、澳大利亚、土耳其等国家和地区从事健康食品行业的一百五十多位专家、行业协会代表以及企业高层主管踊跃参与了这次国际性的行业盛会。
  • 辉山牛奶与首届乡村喜剧晚会共舞元宵,实现品牌与文化的深度融合

    2024辽宁省首届乡村喜剧晚会于2月24日元宵佳节在辽宁卫视与全国观众见面,晚会以“和美铁岭年、快乐最东北”为主题,笑星大咖、喜剧演员云集,这也是辽宁卫视举办的首场乡村喜剧晚会。作为本届乡村喜剧晚会的快乐合作伙伴,辉山牛奶与五羊雪糕携手,通过品牌、产品植入的方式深度融合本届乡村喜剧春晚,拉开了龙年营销“不断档”的新序幕。
  • 精锐食品,只做老面包

    安徽精锐食品有限公司,成立于2017年,是安徽宿州萧县招商引资企业。公司位于萧县食品工业园区,紧邻311国道,合徐高速、连霍高速,交通极为便利。公司拥有20000多平米的花园式厂区,固定资产超过3500万元,拥有员工近200余人。
  • 工匠精神|朱德敏:追求卓越、精益求精的“苏米工匠”

    位于绿草荡地区、鱼米之乡——江苏省淮安市淮安区流均镇的江苏硒米农业生物科技有限公司,依托本地含有富硒的35000多亩土地资源,经营富硒粮食种植、水产养殖和销售。在2022年第九届品牌影响力发展论坛暨成果发布活动中,江苏硒米农业生物科技有限公司荣获“2022品牌强国·行业典范企业”称号。

友情链接

Back to top
      联系我们   SiteMap